AstraZeneca
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AstraZeneca generated cash of $10,345,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$6,567,000,000 last year. Net change in cash is therefore -$346,000,000.
Cash Flow
| 2014 | 7.05B | -7.03B | -2.70B |
|---|---|---|---|
| 2015 | 3.32B | -4.23B | 878M |
| 2016 | 4.14B | -3.96B | -1.32B |
| 2017 | 3.57B | -2.32B | -2.93B |
| 2018 | 2.61B | 963M | -2.04B |
| 2019 | 2.96B | -657M | -1.76B |
| 2020 | 4.79B | -285M | -2.20B |
| 2021 | 5.96B | -11.05B | 3.64B |
| 2022 | 9.80B | -2.96B | -6.82B |
| 2023 | 10.34B | -4.06B | -6.56B |
AZN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.98B | 6.03B | 7.54B | 5.22B | 4.67B | 3.17B | 4.92B | 6.05B | 6.16B | 8.99B |
Operating activities | ||||||||||
Net income | 6.89B | 2.50B | -265M | 3.91B | 1.54B | 1.99B | 2.22B | 3.55B | 3.06B | 1.24B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4.93B | 5.48B | 6.53B | 3.14B | 3.76B | 3.75B | 3.03B | 2.35B | 2.85B | 3.28B |
Stock-based compensation expense | 579M | 619M | 615M | 277M | 259M | 0 | 220M | 0 | 211M | 0 |
| Deferred income tax benefit | 579M | 619M | 615M | 277M | 259M | 0 | 220M | 0 | 211M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.42B | -1.34B | -961M | -739M | -898M | 0 | 83M | 0 | 152M | 0 |
Inventories | -669M | 3.94B | 1.57B | -621M | -316M | -13M | -548M | -343M | -315M | 108M |
Accounts payable | 1.42B | 1.16B | 1.40B | 1.72B | 868M | 0 | 415M | 0 | 114M | 0 |
Cash generated by operating activities | 10.34B | 9.80B | 5.96B | 4.79B | 2.96B | 2.61B | 3.57B | 4.14B | 3.32B | 7.05B |
Investing activities | ||||||||||
Purchases Of Investments | -136M | -159M | -184M | -119M | -13M | -102M | -441M | -396M | -57M | -130M |
Investments In Property Plant And Equipment | -1.36B | -2.57B | -2.2B | -2.60B | -2.46B | -1.37B | -1.62B | -2.31B | -2.78B | -2.75B |
Acquisitions Net | -1.17B | -1.06B | -9.43B | -830M | -783M | -536M | -1.96B | -2.89B | -3.07B | -4.53B |
Cash generated by investing activities | -4.06B | -2.96B | -11.05B | -285M | -657M | 963M | -2.32B | -3.96B | -4.23B | -7.03B |
Financing activities | ||||||||||
Common Stock Issued | 33M | 29M | 29M | 30M | 3.52B | 34M | 43M | 47M | 43M | 279M |
Payments for dividends | -4.48B | -4.36B | -3.85B | -3.57B | -3.59B | -3.48B | -3.51B | -3.56B | -3.48B | -3.52B |
Repurchases of common stock | 0 | 0 | 12.41B | 3.04B | 0 | 2.97B | 0 | 2.77B | 0 | 1.40B |
Repayments of term debt | -965M | -1.51B | -4.75B | -1.60B | -1.51B | -1.49B | 574M | -303M | 4.41B | -750M |
Cash used in financing activities | -6.56B | -6.82B | 3.64B | -2.20B | -1.76B | -2.04B | -2.93B | -1.32B | 878M | -2.70B |
Net Change In Cash | -346M | -55M | -1.50B | 2.32B | 552M | 1.49B | -1.75B | -1.12B | -113M | -2.83B |
Cash at end of period | 5.63B | 5.98B | 6.03B | 7.54B | 5.22B | 4.67B | 3.17B | 4.92B | 6.05B | 6.16B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |